Testicular cancer · 7 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
GIP Variant #01 | — | R 18 587 | 21d | — | — | ~4 | ~R 74 348 indirect | — |
TIP Variant #01 | — | R 16 550 | 28d | — | — | ~4 | ~R 66 199 indirect | — |
VIP Variant #01 | — | R 13 835 | 21d | — | — | ~4 | ~R 55 342 indirect | — |
Ifosfamide and Paclitaxel Variant #01 | — | R 9 725 | 21d | — | ~21.3 mo | ~10 | ~R 97 251 PFS proxy · indirect | 2 |
VeIP Variant #01 | — | R 8 275 | 21d | — | — | ~5 | ~R 41 376 indirect | — |
Cisplatin and Epirubicin Variant #01 | — | R 2 911 | 21d | — | — | ~4 | ~R 11 646 PFS proxy · indirect | 1 |
Carboplatin and Etoposide (CE) Variant #01 | — | R 2 301 | 28d | ~4.6 mo | ~10.6 mo | ~7 | ~R 16 108 PFS proxy · indirect | 17 |
7 of 7 regimens shown